Table 1 Demographics
Demographics: Basic demographic and clinical characteristics for 10/10 complete cases | |
Male (%) | 5 (50%) |
Female (%) | 5 (50%) |
Mean age (range) | 34.6 (18 – 64) |
Hispanic | 3 (30%) |
African American | 3 (30%) |
Caucasian | 4 (40%) |
Focal or Multifocal Epilepsy (%) | 3 (30%) |
Generalized Epilepsy (%) | 6 (60%) |
Absence | 1 (10%) |
Antiepileptic drugs (%): baseline | |
 Phenytoin | 1 (1%) |
 Clobazam | 2 (20%) |
 Lacosamide | 3 (30%) |
 Levetiracetam | 4 (40%) |
 Carbamezepine | 2 (20%) |
 Brivaracetam | 2 (10%) |
 Zonasimide | 1 (10%) |
 Lamotrigine | 2 (20%) |
 Topiramate | 1 (10%) |
 Valproate | 1 (10%) |
 Vagal Nerve Stimulator | 2 (20%) |
Demographics: Basic demographic and clinical characteristics for 7/11 dropouts | |
 Male (%) | 3 (43%) |
 Female (%) | 4 (57%) |
 Mean age (range) | 40.6 (18 – 68) |
 Hispanic | 2 (29%) |
 African American | 0 (0%) |
 Caucasian | 5 (71%) |
 Focal or Multifocal Epilepsy (%) | 1 (14%) |
 Generalized Epilepsy (%) | 6 (86%) |
 Absence | 5 (71%) |
Antiepileptic drugs (%): baseline | |
 Phenytoin | 0 (0%) |
 Clobazam | 1 (14%) |
 Lacosamide | 2 (29%) |
 Levetiracetam | 2 (29%) |
 Carbamezepine | 0 (0%) |
 Brivaracetam | 0 (0%) |
 Zonasimide | 2 (29%) |
 Lamotrigine | 5 (71%) |
 Topiramate | 0 (0%) |
 Valproate | 0 (0%) |
 Vagal Nerve Stimulator | 0 (0%) |